Therapeutic effect of a vaccinia colon oncolysate prepared with interleukin-2-gene encoded vaccinia virus studied in a syngeneic CC-36 murine colon hepatic metastasis model

Vaccinia CC-36 murine colon oncolysate (VCO) prepared with interleukin-2-gene encoded recombinant vaccinia virus (IL-2VCO) was used in the treatment of a syngeneic murine colon adenocarcinoma (CC-36) hepatic metastasis to test the beneficial effect of the interleukin-2-gene encoded vaccinia virus ov...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Immunology, Immunotherapy Immunotherapy, 1994-07, Vol.38 (4), p.259-264
Main Authors: MUTHUKUMARAN SIVANANDHAM, SCOGGIN, S. D, TANAKA, N, WALLACK, M. K
Format: Article
Language:English
Subjects:
Adenocarcinoma - immunology
Animals
Antineoplastic agents
Biological and medical sciences
Colonic Neoplasms - immunology
Cytotoxicity, Immunologic
Humans
Immunotherapy
Immunotherapy, Active
Interleukin-2 - biosynthesis
Interleukin-2 - genetics
Interleukin-2 - therapeutic use
Liver Neoplasms, Experimental - secondary
Liver Neoplasms, Experimental - therapy
Lymphocytes - immunology
Male
Medical sciences
Mice
Mice, Inbred BALB C
Ogininal
Pharmacology. Drug treatments
Recombinant Proteins - therapeutic use
Tumor Cells, Cultured
Vaccinia virus - genetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Vaccinia CC-36 murine colon oncolysate (VCO) prepared with interleukin-2-gene encoded recombinant vaccinia virus (IL-2VCO) was used in the treatment of a syngeneic murine colon adenocarcinoma (CC-36) hepatic metastasis to test the beneficial effect of the interleukin-2-gene encoded vaccinia virus over a control recombinant vaccinia virus in producing a vaccinia oncolysate tumor cell vaccine. Results suggest that the IL-2VCO treatment significantly reduced the hepatic tumor burden in comparison with the controls that received either IL-2-gene-encoded recombinant vaccinia virus or a plain recombinant vaccinia virus or vaccinia oncolysate prepared with the plain recombinant virus. The survival of mice treated with IL-2VCO was also improved in comparison with mice treated with other preparations. The induction of a cytolytic T lymphocyte response was examined to elucidate the mechanism of the induction of antitumor responses in IL-2VCO-treated mice. Fresh peripheral blood lymphocytes (PBL) isolated from IL-2VCO-treated mice showed a higher cytolytic activity against CC-36 tumor cell target when compared to PBL from the mice of other treatment groups, suggesting that the IL-2VCO induced an antitumor cytolytic T lymphocyte response. These results suggest that a vaccinia oncolysate, prepared with recombinant vaccinia virus encoding an immunomodulating cytokine gene will enhance antitumor responses in the host.
ISSN:0340-7004
1432-0851
DOI:10.1007/BF01533517